OpenAI CEO Sam Altman took the technology world by surprise on Thursday with the release of Operator, his company's first AI agent that can act

Retro Biosciences will back clinical trials for three drugs—including a potential Alzheimer’s disease treatment set to begin studies this year.

OpenAI CEO Sam Altman will brief U.S. officials on super-agents—AI systems set to revolutionize software development, finance, and event planning.

Retro Biosciences Inc., a startup using artificial intelligence to discover new drugs, is reportedly raising $1 billion in funding to support its research. The Financial Times today cited sources as saying that Sam Altman is participating in the investment. He previously provided the initial $180 million funding round that helped launch Retro.

Tensions between technology leaders Elon Musk and OpenAI CEO Sam Altman were on full display this week after the Tesla CEO slammed the new artificial intelligence (AI) infrastructure project,

President Donald Trump spoke with OpenAI CEO Sam Altman by phone Friday, ahead of the AI infrastructure announcement, CNBC has learned.

OpenAI CEO Sam Altman suggested Elon Musk cares more about his businesses than he does the country, shortly after he referred to Musk as "the most inspiring entrepreneur of our time."

"And of course it's smarter than us. Of course, it can do things we can't, but also who really cares? I think it's only weird for us in this one transition time."

Elon Musk asked a judge to block OpenAI's attempt to transition from nonprofit to for-profit. It's not the first time he's feuded with CEO Sam Altman.

Though Altman said he likely wouldn’t agree with Trump on “everything,” the OpenAI CEO said he believes “he will be incredible for the country in many ways.”